Patents by Inventor Clint STALNECKER

Clint STALNECKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1
    Publication number: 20210317115
    Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
    Type: Application
    Filed: November 17, 2020
    Publication date: October 14, 2021
    Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
  • Labeled glutaminase proteins, isolated glutaminase protein mutants, methods of use, and kit
    Patent number: 11046945
    Abstract: The present invention relates to a labeled glutaminase (GLS) protein comprising a GLS protein and a fluorescent reporter group attached to the GLS protein, wherein the fluorescent reporter group is attached to the GLS protein within the glutaminase domain pfam04960 of GLS. The present invention also relates to isolated glutaminase protein mutants. Also disclosed is a method of screening for compounds that allosterically bind to a glutaminase protein. The present invention also relates to a method of identifying compounds that inhibit or stabilize tetramer formation of glutaminase protein. The present invention further relates to a screening kit for compounds that inhibit or stabilize tetramer formation.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 29, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Clint A. Stalnecker, Jon W. Erickson, Sekar Ramachandran, Rick Cerione
  • Inhibitors of kidney-type glutaminase, GLS-1
    Patent number: 10889585
    Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: January 12, 2021
    Assignees: CORNELL UNIVERSITY, ITHACA COLLEGE
    Inventors: Richard Cerione, Kristin Cerione, Clint Stalnecker, Scott Ulrich
  • Method of screening compounds
    Patent number: 10767212
    Abstract: The present technology relates to kidney-type glutaminase (GLS) proteins that have a phenylalanine to tryptophan substitution at the position corresponding to residue 322 of human glutaminase C (GAC), and methods of using such proteins to screen for compounds that bind to the activation loop of GLS and/or modulate glutaminase activity of GLS.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: September 8, 2020
    Assignee: Cornell University
    Inventors: Richard Cerione, Jon W Erickson, Clint A Stalnecker
  • INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1
    Publication number: 20200216448
    Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
  • Inhibitors of kidney-type glutaminase, GLS-1
    Patent number: 10526322
    Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
    Type: Grant
    Filed: December 5, 2015
    Date of Patent: January 7, 2020
    Assignees: Cornell University, Ithaca College
    Inventors: Richard Cerione, Kristin Cerione, Clint Stalnecker, Scott Ulrich
  • DIRECT ASSAY FOR ALLOSTERIC MODULATORS OF GLUTAMINASE
    Publication number: 20180100178
    Abstract: The present technology relates to GLS proteins that have a phenylalanine to tryptophan substitution at the position corresponding to residue 322 of human GAC, and methods of using such proteins to screen for compounds that bind to the activation loop of GLS and/or modulate glutaminase activity of GLS.
    Type: Application
    Filed: September 25, 2017
    Publication date: April 12, 2018
    Inventors: Richard Cerione, Jon W Erickson, Clint A Stalnecker
  • INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1
    Publication number: 20170362221
    Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
    Type: Application
    Filed: December 5, 2015
    Publication date: December 21, 2017
    Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
  • LABELED GLUTAMINASE PROTEINS, ISOLATED GLUTAMINASE PROTEIN MUTANTS, METHODS OF USE, AND KIT
    Publication number: 20160002619
    Abstract: The present invention relates to a labeled glutaminase (GLS) protein comprising a GLS protein and a fluorescent reporter group attached to the GLS protein, wherein the fluorescent reporter group is attached to the GLS protein within the glutaminase domain pfam04960 of GLS. The present invention also relates to isolated glutaminase protein mutants. Also disclosed is a method of screening for compounds that allosterically bind to a glutaminase protein. The present invention also relates to a method of identifying compounds that inhibit or stabilize tetramer formation of glutaminase protein. The present invention further relates to a screening kit for compounds that inhibit or stabilize tetramer formation.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 7, 2016
    Inventors: Clint A. STALNECKER, Jon W. ERICKSON, Sekar RAMACHANDRAN, Rick CERIONE